Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Companyâs lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļIMNN
āļāļ·āđāļāļāļĢāļīāļĐāļąāļImunon Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 27, 1993
āļāļĩāļāļĩāđāļLindborg (Stacy R)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ25
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 27
āļāļĩāđāļāļĒāļđāđ997 Lenox Dr Ste 100
āđāļĄāļ·āļāļLAWRENCEVILLE
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ08648
āđāļāļĢāļĻāļąāļāļāđ16098969100
āđāļ§āđāļāđāļāļāđhttps://imunon.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļIMNN
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 27, 1993
āļāļĩāļāļĩāđāļLindborg (Stacy R)
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Chief Executive Officer, President and Director
Chief Executive Officer, President and Director
Dr. Douglas Vincent Faller, M.D., Ph.D.
Dr. Douglas Vincent Faller, M.D., Ph.D.
Chief Medical Officer
Mr. James E. Dentzer
Independent Director
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Ms. Christine A. Pellizzari
Ms. Christine A. Pellizzari
Independent Director
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
Ms. Susan Eylward
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
Ms. Kimberly Graper
Interim Chief Financial Officer
Interim Chief Financial Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Chief Executive Officer, President and Director
Chief Executive Officer, President and Director
Dr. Douglas Vincent Faller, M.D., Ph.D.
Dr. Douglas Vincent Faller, M.D., Ph.D.
Chief Medical Officer
Mr. James E. Dentzer
Independent Director
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Ms. Christine A. Pellizzari
Ms. Christine A. Pellizzari
Independent Director